Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

Core Insights - Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases [3] Group 1: Company Overview - Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia [3] - The company plans to utilize its intracellular delivery platform to design other fusion proteins targeting additional rare diseases characterized by deficiencies in intracellular bioactive compounds [3] Group 2: Upcoming Events - Larimar's management team will present at the Leerink Partners Global Healthcare Conference on March 10, 2026, at 8:40 AM ET [2] - The company will also participate in The Citizens Life Sciences Conference on March 11, 2026, at 4:00 PM ET [2] - Webcast links for both presentations are provided for investor access [2]